Compare TGL & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGL | GOVX |
|---|---|---|
| Founded | 2020 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7M | 3.0M |
| IPO Year | 2022 | 1996 |
| Metric | TGL | GOVX |
|---|---|---|
| Price | $3.57 | $2.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $240.00 |
| AVG Volume (30 Days) | ★ 2.1M | 279.9K |
| Earning Date | 12-01-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.53 | N/A |
| EPS | ★ 16.03 | N/A |
| Revenue | ★ $5,169,784.00 | $2,489,145.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 121.83 | N/A |
| 52 Week Low | $0.14 | $0.11 |
| 52 Week High | $587.80 | $1,095.50 |
| Indicator | TGL | GOVX |
|---|---|---|
| Relative Strength Index (RSI) | 81.19 | 57.20 |
| Support Level | $2.59 | $0.11 |
| Resistance Level | $4.27 | $4.60 |
| Average True Range (ATR) | 0.12 | 0.23 |
| MACD | 0.42 | 0.33 |
| Stochastic Oscillator | 75.82 | 66.43 |
Treasure Global Inc has created an online-to-offline e-commerce platform business model that offers consumers and merchants instant rebates and affiliate cashback programs, while providing a seamless e-payment solution with rebates in both e-commerce and physical retail or merchant settings. Its product is an internet application branded as the ZCITY app, a digital rewards and lifestyle platform based in Malaysia that uses artificial intelligence to offer personalized shopping deals, discounts, and rebates, and targets consumers by providing personalized deals based on their purchase history, location, and preferences. The company has two reportable segments: the ZCITY platform, which generates the maximum revenue, and Customized software development service.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.